ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

ORIC Pharmaceuticals, a clinical stage oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. PT. CEO Jacob Chacko will provide an overview of the company, which is focused on overcoming therapeutic resistance in cancer treatments. Their lead candidate, ORIC-101, is currently in Phase 1b trials for metastatic prostate cancer and advanced solid tumors in combination with Xtandi and Abraxane, respectively. A live webcast of the presentation will be available on their website.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive officer, will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 12:40 p.m. PT. 

A live webcast will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with (1) Xtandi (enzalutamide) in metastatic prostate cancer and (2) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC’s other product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers. Beyond these four product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com 
info@oricpharma.com 

 

FAQ

When will ORIC Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

ORIC Pharmaceuticals will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 12:40 p.m. PT.

Who is presenting for ORIC Pharmaceuticals at the conference?

Jacob Chacko, M.D., the CEO of ORIC Pharmaceuticals, will present at the conference.

How can I watch the ORIC Pharmaceuticals presentation live?

The presentation will be available via a live webcast on the investor section of ORIC Pharmaceuticals' website.

What is ORIC Pharmaceuticals' focus area?

ORIC Pharmaceuticals focuses on developing treatments that address mechanisms of therapeutic resistance in oncology.

What are the current trials for ORIC Pharmaceuticals' lead product candidate?

ORIC-101 is currently in two Phase 1b trials: one in combination with Xtandi for metastatic prostate cancer and another with Abraxane for advanced or metastatic solid tumors.